Literature DB >> 24659663

Serum levels of cytokines and prevalence of autoantibodies in lymphoma patients and their prognostic value.

Hava Uskudar Teke1, Zafer Gulbas, Cengiz Bal.   

Abstract

PURPOSE: Recent studies have shown that cytokines and autoantibodies that have an important role in pathogenesis of lymphoma can be used as prognostic markers. In this study, we aimed to determine the prognostic significance of a large panel of serum cytokines and compare them with a control group, and also to see for any relationship with known classical prognostic factors, the frequency of autoantibody positivity and autoimmune phenomena in patients with untreated non Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL).
METHODS: For cytokine studies blood samples were obtained in the morning after fasting for at least 8-12 h. We used empty tubes for serum and EDTA-containing tubes for plasma samples. Blood samples were then transferred to laboratory in 5-10 min, plasma and sera were separated by centrifugation, and stored at -75 ?C until assayed. Then, all sera were warmed to room temperature. All the cytokine levels were studied with Panomics Company ProcartaTM Human Cytokine multiplex kits.
RESULTS: In lymphoma patients INF-ggr; was related with thyroglobulin antibody positivity and IL-6 with direct Coombs positivity. IL-6 was the most important cytokine connected with lymphopenia and B symptoms in lymphoma patients. IL-1β, INF-γ, IL-2 and IL-4 were markers associated with poor prognosis in HL. At least one autoantibody was positive in 50% of NHL and HL patients. At least one antiphospholipid antibody (APA) was positive in 26% of NHL and 38% of HL patients.
CONCLUSION: TNF-α and IL-6 are poor prognostic factors that may be included in the International Prognostic Index (IPI). To understand the effects of autoantibodies in the prognosis of HL and NHL, long-term patient follow-up studies are required.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24659663

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  4 in total

1.  Lymphomas diagnosed in an internal medicine department compared to lymphomas diagnosed in other departments: Clinical and outcome differences.

Authors:  Benoit Pernot; Emmanuel Gyan; François Maillot; Penelope Hodges; Marjan Ertault; Nicole Ferreira-Maldent
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

Review 2.  Antiphospholipid Antibodies and Lipids in Hematological Malignancies.

Authors:  Sonia Guadalupe Barreno-Rocha; Sandra Guzmán-Silahua; Sinaí-Del-Carmen Rodríguez-Dávila; Guadalupe Estela Gavilanez-Chávez; Ernesto Germán Cardona-Muñoz; Carlos Riebeling-Navarro; Benjamín Rubio-Jurado; Arnulfo Hernán Nava-Zavala
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

3.  A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma.

Authors:  Faezeh Ajorloo; Mohammad Vaezi; Alireza Saadat; Seyed Reza Safaee; Behrouz Gharib; Mostafa Ghanei; Seyed Davar Siadat; Farzam Vaziri; Abolfazl Fateh; Mehrdad Pazhouhandeh; Behrouz Vaziri; Reza Moazemi; Fereidoun Mahboudi; Fatemeh Rahimi Jamnani
Journal:  PLoS One       Date:  2017-09-11       Impact factor: 3.240

4.  Bone marrow uptake of 18F-fluorodeoxyglucose in Hodgkin lymphoma without bone involvement: comparison between patients with and without B symptoms.

Authors:  Rômulo Hermeto Bueno do Vale; Daniela Andrade Ferraro; Paulo Schiavom Duarte; Giovana Carvalho; Marcos Santos Lima; George Barbério Coura Filho; Marcelo Tatit Sapienza; Carlos Alberto Buchpiguel
Journal:  Radiol Bras       Date:  2018 Mar-Apr
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.